BRAF and lung adenocarcinoma: The progression-free survival (PFS) of first-line combination of atezolizumab with platinum-based chemotherapy and sequential second-line treatment with BRAFi Vemurafenib are 20 and 5.5 months, respectively.<h4>Conclusion</h4>This case shows a durable response to ICPi in <i>BRAF</i> V600E non-smoking lung adenocarcinoma with PFS of 20 months under first-line atezolizumab plus chemotherapy treatment.